Table 1.
Trials on SLIT efficacy carried out in children with asthma.
| Author, Year | Trial | Allergen Extract | Age (Years) | Population (Active/Controls) | AIT Duration (Months) | Outcome |
|---|---|---|---|---|---|---|
| Tari et al., 1990 [21] | RDBPC | HDM | <12 | 30/28 | 30 | ↓ bronchial hyperreactivity |
| Hirsch et al., 1997 [22] | RDBPC | HDM | 6–16 | 15/15 | 12 | ↓ asthma symptoms |
| Paino et al., 2000 [23] | RDBPC | HDM | 8–15 | 12/12 | 24 | ↓ asthma symptoms ↓ medication use |
| Bahçeciler et al., 2001 [24] | RDBPC | HDM | 8–15 | 7/8 | 6 | ↓asthma attacks ↑PEF |
| Ippoliti et al., 2003 [25] | RDBPC | HDM | 5–12 | 47/39 | 6 | ↓asthma symptoms ↓ ECP, IL-13, PRL |
| Lue et al., 2006 [26] | RDBPC | HDM | 6–12 | 10/10 | 6 | ↓asthma symptoms ↑ IgG4, total IgE ↓ eosinophil count ↑ lung function |
| Niu et al., 2006 [27] | RDBPC | HDM | 6–12 | 49/48 | 6 | ↓asthma symptoms ↓ lung function |
| Pham-Thi et al., 2007 [28] | RDBPC | HDM | 5–16 | 55/56 | 18 | ↓SPT reactivity ↑ lung function |
| Eifan et al., 2010 [51] | RCT | HDM | 5–10 | 32/16 | 24 | ↓asthma symptoms ↓ medication score ↓ VAS ↓sIgE and SPT for HDM |
| Keles et al., 2011 [52] | RCT | HDM | 5–12 | 48/12 | 18 | ↓asthma attacks, ↓ inhaled steroid dosage |
| Yukselen et al., 2012 [53] | RDBPC | HDM | 6–14 | 21/10 | 12 | ↓ asthma symptoms ↓ medication use ↓ VAS ↓sIgE and SPT for HDM |
| Rolinck-Werninghaus et al., 2004 [55] | RDBPC | Grass | 3–14 | 20/19 | 32 | ↓ medication score |
| Bufe et al., 2009 [54] | RDBPC | Grass | 5–16 | 126/127 | 10 | ↓ asthma symptoms |
| Stelmach et al., 2009 [56] | RDBPC | Grass | 6–17 | 25/25 | 24 | ↓ asthma symptoms ↑ FEV1 ↓ medication use |
| Vourdas et al., 1998 [58] | RDBPC | Olive | 7–17 | 33/29 | 24 | ↓ asthma symptoms |
| La Rosa et al., 1999 [31] | RDBPC | Parietaria | 6–14 | 20/21 | 24 | ↓ rhinitis symptoms ↓ SPT ↑ sIgG4 |
| Pajno et al., 2004 [59] | RDBPC | Parietaria | 8–14 | 15/15 | 24 | ↓ bronchial hyperreactivity |
| Valovirta et al., 2006 [30] | RDBPC | Tree pollen | 5–15 | 59/29 | 17 | ↓ symptoms ↓ medication use |
| Nolte et al., 2020 [61] | RDBPC | Ragweed | 5–17 | 513/512 | 7 | ↓ asthma symptoms ↓ short-acting beta2-agonist use |
DBPC, double-blind placebo-controlled; EBC, exhaled breath condensate; ECP, eosinophil cationic protein; FEV1, forced expiratory volume in the 1st second; HDM, house dust mite; IL-13, interleukin 13; PEF, peak expiratory flow; PRL, prolactin; RCT, randomized controlled study; SPT, skin prick test; VAS, visual analog scale; ↑, increased; ↓, diminished.